Bavencio Intravenous 200 mg Special Drug Use results Survey (Maintenance following chemotherapy treatment in curatively unresectable urothelial carcinoma)

Bavencio Intravenous 200 mg Special Drug Use results Survey (Maintenance following chemotherapy treatment in curatively unresectable urothelial carcinoma) - Bavencio Special Drug Use-results Survey (urothelial carcinoma)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043435

Enrollment

250

Registered

2021-02-25

Start date

2021-02-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maintenance following chemotherapy treatment in curatively unresectable urothelial carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who received at least one dose of this drug during the enrollment period.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
The safety profile of Bavencio Intravenous 200 mg in clinical practice is to be further characterized, by estimating the incidence of events listed as safety specifications, Urinary tract infection and Hematuria in this surveillance study.	—

Secondary

Measure	Time frame
To investigate the effectiveness of Bavencio Intravenous 200 mg in patients with Maintenance following chemotherapy treatment in curatively unresectable urothelial carcinoma in terms of time to treatment failure(TTF), time to first subsequent therapy (TFST) and overall survival (OS) in clinical practice.	—

Countries

Japan

Contacts

Public ContactTaito Ito

Merck Biopharma Co., Ltd. PMS Planning & Strategy, Medical Department

taito.ito@merckgroup.com03-6756-0805

Outcome results